Table 3.

Demographic data of ABPA patients with and without AR receiving omalizumab

	All participants (n = 14)	With AR (n = 10)	Without AR (n = 4)	P
Age, years	53 (range, 18–82)	54 (range, 18–82)	53 (range, 47–61)	0.88
Female	6	6	0	0.09
History of asthma, years	9 (range, 0.5–30)	10 (range, 0.5–30)	4.5 (range, 1.8–10.8)	0.25
Antifungal agents	4	3	1	0.001
Bronchiectasis	7	5	2	1.00
Follow-up (month)	21 (range, 6–40)	23 (range, 8–40)	21 (range, 15–26)	0.78
Duration of omalizumab	16 (range, 4–40)	23 (range, 5–40)	8 (range, 4–25)	0.09

ABPA, allergic bronchopulmonary aspergillosis; AR, allergic rhinitis